Savara Inc. Common Stock (SVRA)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with earning power, and Savara has none yet. It is a 70-employee clinical-stage biotech developing molgramostim for autoimmune pulmonary alveolar proteinosis, a rare respiratory disease. No revenue is reported in the filed periods. The net losses are widening: fiscal 2023 lost $54.7M, fiscal 2024 lost $95.9M, and fiscal 2025 lost $118.8M. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $40.2M; fiscal Q1 2026 lost $37.3M. Trailing free cash flow is -$110.7M, an -11.3% FCF yield on the $982.1M market cap. The stock closed at $4.78 on 2026-10-13, with negative EPS of -$0.58, a FairStock-calculated P/E of -8.24, and P/B of 6.93. FairStock-calculated ROE is -105.48% and ROCE is -50.14%.

In plain English: Savara is a drug development company with no product sales, testing an inhaled treatment for a rare lung disease. It has lost money every year shown, burns cash heavily, and losses have grown. At $4.78, the stock looks speculative and expensive relative to its current financial results because there is no revenue or profit to support the price yet.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer